Delivery Order SPE2DB20D1100-SPE2DB25FE5N2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pen injections valued at $13,018.75 under a firm fixed-price contract. The delivery order, which concludes on September 11, 2025, represents a competitively awarded non-set-aside procurement supporting the federal government's pharmaceutical supply requirements. The contract will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $391,967.30. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 10, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's broader pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $17,964.65 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injections on August 28, 2025, with an ultimate completion date of August 29, 2025. The contract utilizes firm fixed price pricing with no set-aside designation, indicating competitive award. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania will serve as the place of performance for this pharmaceutical delivery. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a $29,637.02 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This contract represents a firm fixed-price delivery order with an ultimate completion date of September 9, 2025, and carries no set-aside designation, indicating it was awarded through open competition. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- On August 5, 2025, the Defense Logistics Agency awarded a delivery order valued at $48,364.69 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injections. This firm fixed-price delivery order, which is not set-aside designated, represents a competitive award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The products will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $29,850.86 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, designated as a firm fixed price delivery order with an ultimate completion date of July 28, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's established...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $13,735.17. This contract represents a firm fixed price delivery order with no set-aside designation, issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the...
- The Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $59,030.74. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The order is scheduled for completion by September 10, 2025, and will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE5N2Delivery Order
The Defense Logistics Agency awarded a $95,638.45 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 mL pen injections. The contract, which is not set-aside and carries a firm fixed-price structure, is scheduled for completion by September 10, 2025, with performance occurring at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction within AmerisourceBergen's larger federal pharmaceutical supply relationship. This award operates under AmerisourceBergen's comprehensive Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen supplies a broad range of medications and medical products to support military and veteran healthcare systems, including specialty drugs, brand-name and generic pharmaceuticals, vaccines, and medical devices. The company's sustained federal contracting presence and competitive award history demonstrate its capability to fulfill the Defense Logistics Agency's pharmaceutical procurement requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $95.6k | 9/9/25 |